The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
Abstract
PTK7 is a tumor-initiating cell antigen, which can be targeted with an antibody-drug conjugate to confer sustained tumor regressions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Bevacizumab plus ipilimumab in patients with metastatic melanoma
Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593
Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7433 · Cited by 182 · cited 1×
“ADCs that effectively and specifically target TICs should offer a therapeutic advantage by limiting the opportunity for acquired resistance and by sparing normal tissues from damage (8, 11, 12).”
Background
Cited by
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Recent advances in therapeutic strategies for triple-negative breast cancer
Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01341-0 · Cited by 956
Self-citationWnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Katoh, M. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4129 · Cited by 465
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Majeed, U., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01121-2 · Cited by 266
Metadata
- Authors
- Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., Dushin, R., Aujay, M., Lee, C., Ramoth, H., Milton, M., Hampl, J., Lazetic, S., Pulito, V., Rosfjord, E., Sun, Y., King, L., Barletta, F., Betts, A., Guffroy, M., Falahatpisheh, H., O’Donnell, C. J., Stull, R., Pysz, M., Escarpe, P., Liu, D., Foord, O., Gerber, H. P., Sapra, P., & Dylla, S. J.
- Venue
- Science Translational Medicine
- Published
- 2017-01-11
- Volume
- 9
- Issue
- 372
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2574836938
- Cited by
- 163
- References
- 5
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. https://app.cochat.ai/papers/10.1126/scitranslmed.aag2611
- The paper
- Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., Dushin, R., Aujay, M., Lee, C., Ramoth, H., Milton, M., Hampl, J., Lazetic, S., Pulito, V., Rosfjord, E., . . . Dylla, S. J. (2017). A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aag2611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.